A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers

Completed · Phase 2 · Has a placebo group

Conditions studied: Lung Cancer

In brief

To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient between the enzastaurin and placebo groups.

Key facts

Study ID

NCT00414960

Run by

Eli Lilly and Company

People needed

40

Starts

2007-12-01

Expected to finish

2010-09-01

Last updated by the study team

2020-09-21

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Sputum atypia participants with normal sputum cytology will be removed from the study)
• Metaplasia or dysplasia on at least one bronchoscopy specimen
• History of cigarette smoking ≥30 Pack Years
• Quit smoking ≥1 year prior to study entry
• Able to undergo bronchoscopy and helical computed tomography (CT) scanning of the chest
• Able to swallow tablets

You may not qualify if…

• Blood clotting abnormalities
• Current smoking within the past 1 year
• Unwillingness to abstain from smoking while enrolled in the clinical trial or unwillingness to avoid significant second hand smoke exposure
• Evidence for lung cancer or carcinoma in situ
• Active cardiovascular disease
• Current illicit drug or alcohol abuse

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.